Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor.
Cardiovascular events
Chronic kidney disease
Cytokines oxalate
Dialysis
Interleukin-16
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 May 2024
17 May 2024
Historique:
received:
27
12
2023
accepted:
09
05
2024
medline:
18
5
2024
pubmed:
18
5
2024
entrez:
17
5
2024
Statut:
epublish
Résumé
Oxalate, a uremic toxin that accumulates in dialysis patients, is associated with cardiovascular disease. As oxalate crystals can activate immune cells, we tested the hypothesis that plasma oxalate would be associated with cytokine concentrations and cardiovascular outcomes in dialysis patients. In a cohort of 104 US patients with kidney failure requiring dialysis (cohort 1), we measured 21 inflammatory markers. As IL-16 was the only cytokine to correlate with oxalate, we focused further investigations on IL-16. We searched for associations between concentrations of IL-16 and mortality and cardiovascular events in the 4D cohort (1255 patients, cohort 2) and assessed further associations of IL-16 with other uremic toxins in this cohort. IL-16 levels were positively correlated with pOx concentrations (ρ = 0.39 in cohort 1, r = 0.35 in cohort 2) and were elevated in dialysis patients when compared to healthy individuals. No significant association could be found between IL-16 levels and cardiovascular events or mortality in the 4D cohort. We conclude that the cytokine IL-16 correlates with plasma oxalate concentrations and is substantially increased in patients with kidney failure on dialysis. However, no association could be detected between IL-16 concentrations and cardiovascular disease in the 4D cohort.
Identifiants
pubmed: 38760468
doi: 10.1038/s41598-024-61808-7
pii: 10.1038/s41598-024-61808-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11323Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 515514134
Organisme : Deutsche Forschungsgemeinschaft
ID : 515514134
Organisme : Deutsche Forschungsgemeinschaft
ID : 515514134
Organisme : Deutsche Forschungsgemeinschaft
ID : 515514134
Organisme : Deutsche Forschungsgemeinschaft
ID : 515514134
Organisme : Deutsche Forschungsgemeinschaft
ID : 394046635
Organisme : NIDDK NIH HHS
ID : R01DK033793
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Himmelfarb, J., Vanholder, R., Mehrotra, R. & Tonelli, M. The current and future landscape of dialysis. Nat. Rev. Nephrol. 16, 573–585 (2020).
pubmed: 32733095
pmcid: 7391926
doi: 10.1038/s41581-020-0315-4
Johansen, K. L. et al. US renal data system 2021 annual data report: Epidemiology of kidney disease in the United States. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 79, A8–A12 (2022).
doi: 10.1053/j.ajkd.2022.02.001
Cobo, G., Lindholm, B. & Stenvinkel, P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol. Dial Transplant. 33, 35–40 (2018).
doi: 10.1093/ndt/gfy175
Zimmermann, J., Herrlinger, S., Pruy, A., Metzger, T. & Wanner, C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 55, 648–658 (1999).
pubmed: 9987089
doi: 10.1046/j.1523-1755.1999.00273.x
Duranton, F. et al. Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol. 23, 1258–1270 (2012).
pubmed: 22626821
pmcid: 3380651
doi: 10.1681/ASN.2011121175
Pertosa, G., Grandaliano, G., Gesualdo, L. & Schena, F. P. Clinical relevance of cytokine production in hemodialysis. Kidney Int. 58, S104–S111 (2000).
doi: 10.1046/j.1523-1755.2000.07613.x
Stenvinkel, P. et al. IL-10, IL-6, and TNF-α: Central factors in the altered cytokine network of uremia–the good, the bad, and the ugly. Kidney Int. 67, 1216–1233 (2005).
pubmed: 15780075
doi: 10.1111/j.1523-1755.2005.00200.x
Perinpam, M. et al. Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. Clin. Biochem. 50, 1014–1019 (2017).
pubmed: 28764885
pmcid: 5705406
doi: 10.1016/j.clinbiochem.2017.07.017
Hoppe, B. et al. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int. 56, 268–274 (1999).
pubmed: 10411702
doi: 10.1046/j.1523-1755.1999.00546.x
Worcester, E. M., Nakagawa, Y., Bushinsky, D. A. & Coe, F. L. Evidence that serum calcium oxalate supersaturation is a consequence of oxalate retention in patients with chronic renal failure. J. Clin. Invest. 77, 1888–1896 (1986).
pubmed: 3711339
pmcid: 370548
doi: 10.1172/JCI112516
Waikar, S. S. et al. Association of urinary oxalate excretion with the risk of chronic kidney disease progression. JAMA Intern. Med. 179, 542–551 (2019).
pubmed: 30830167
pmcid: 6450310
doi: 10.1001/jamainternmed.2018.7980
Liu, Y. et al. Dysregulated oxalate metabolism is a driver and therapeutic target in atherosclerosis. Cell Rep. 36, 109420 (2021).
pubmed: 34320345
pmcid: 8363062
doi: 10.1016/j.celrep.2021.109420
Mulay, S. R. et al. Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice. Am. J. Physiol.-Renal. Physiol. 310, F785–F795 (2016).
pubmed: 26764204
pmcid: 5504458
doi: 10.1152/ajprenal.00488.2015
Pfau, A. et al. High oxalate concentrations correlate with increased risk for sudden cardiac death in dialysis patients. J. Am. Soc. Nephrol. 32, 2375–2385 (2021).
pubmed: 34281958
pmcid: 8729829
doi: 10.1681/ASN.2020121793
Ludwig-Portugall, I. et al. An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. Kidney Int. 90, 525–539 (2016).
pubmed: 27262364
doi: 10.1016/j.kint.2016.03.035
Mulay, S. R. et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. J. Clin. Invest. 123, 236–246 (2013).
pubmed: 23221343
doi: 10.1172/JCI63679
Schunk, S. J. et al. Interleukin-1α is a central regulator of leukocyte-endothelial adhesion in myocardial infarction and in chronic kidney disease. Circulation 144, 893–908 (2021).
pubmed: 34192892
doi: 10.1161/CIRCULATIONAHA.121.053547
Stelzhammer, V. et al. Proteomic changes in serum of first onset, antidepressant drug-naïve major depression patients. Int. J. Neuropsychopharm. 17, 1599–1608 (2014).
doi: 10.1017/S1461145714000819
Kawabata, K. et al. IL-16 expression is increased in the skin and sera of patients with systemic sclerosis. Rheumatology 59, 519–523 (2020).
pubmed: 31377804
Lee, S. et al. Circulating interleukin-16 in systemic lupus erythematosus. Rheumatology 37, 1334–1337 (1998).
doi: 10.1093/rheumatology/37.12.1334
Purzycka-Bohdan, D. et al. Assessment of interleukin 16 serum levels and skin expression in psoriasis patients in correlation with Clinical severity of the disease. PLoS ONE 11, e0165577 (2016).
pubmed: 27788245
pmcid: 5082815
doi: 10.1371/journal.pone.0165577
Lichtenauer, M. et al. Elevated plasma levels of interleukin-12p40 and interleukin-16 in overweight adolescents. Biomed. Res. Int. 1, 7 (2015).
Alexandrakis, M. G. et al. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. Am. J. Hematol. 75, 101–106 (2004).
pubmed: 14755377
doi: 10.1002/ajh.10444
Long, S.-F., Chen, G.-A. & Fang, M.-S. Levels of interleukin-16 in peripheral blood of 52 patients with multiple myeloma and its clinical significance. Int. J. Clin. Exp. Med. 8, 22520–22524 (2015).
pubmed: 26885237
pmcid: 4730023
Yang, H., Han, Y., Wu, L. & Wu, C. Diagnostic and prognostic value of serum interleukin-16 in patients with gastric cancer. Mol. Med. Rep. 16, 9143–9148 (2017).
pubmed: 28990054
doi: 10.3892/mmr.2017.7688
Roth, S., Solbach, W. & Laskay, T. IL-16 and MIF: Messengers beyond neutrophil cell death. Cell Death Dis. 7, e2049–e2049 (2016).
pubmed: 26775701
pmcid: 4816173
doi: 10.1038/cddis.2015.388
Cruikshank, W. W., Kornfeld, H. & Center, D. M. Interleukin-16. J. Leukoct. Biol, 67, 757–766 (2000).
doi: 10.1002/jlb.67.6.757
Zhang, Y. et al. Processing and activation of pro-interleukin-16 by caspase-3. J. Biol. Chem. 273, 1144–1149 (1998).
pubmed: 9422780
doi: 10.1074/jbc.273.2.1144
Elssner, A., Doseff, A. I., Duncan, M., Kotur, M. & Wewers, M. D. IL-16 is constitutively present in peripheral blood monocytes and spontaneously released during apoptosis. J. Immunol. 172, 7721–7725 (2004).
pubmed: 15187155
doi: 10.4049/jimmunol.172.12.7721
Richmond, J., Tuzova, M., Cruikshank, W. & Center, D. Regulation of cellular processes by interleukin-16 in homeostasis and cancer. J. Cell. Physiol. 229, 139–147 (2014).
pubmed: 23893766
doi: 10.1002/jcp.24441
Roth, S. et al. Secondary necrotic neutrophils release interleukin-16C and macrophage migration inhibitory factor from stores in the cytosol. Cell Death Discov. 1, 15056 (2015).
pubmed: 27551482
pmcid: 4979515
doi: 10.1038/cddiscovery.2015.56
McFadden, C. et al. Preferential migration of T regulatory cells induced by IL-16. J. Immunol. 179, 6439–6445 (2007).
pubmed: 17982032
doi: 10.4049/jimmunol.179.10.6439
Grönberg, C. et al. Endarterectomy patients with elevated levels of circulating IL-16 have fewer cardiovascular events during follow-up. Cytokine 85, 137–139 (2016).
pubmed: 27344024
doi: 10.1016/j.cyto.2016.06.009
Park, S. L. et al. p21WAF1 is required for interleukin-16-induced migration and invasion of vascular smooth muscle cells via the p38MAPK/Sp-1/MMP-9 pathway. PLoS ONE 10, e0142153 (2015).
pubmed: 26544695
pmcid: 4636239
doi: 10.1371/journal.pone.0142153
Schernthaner, C. et al. Elevated plasma levels of interleukin-16 in patients with acute myocardial infarction. Medicine 96, e8396 (2017).
pubmed: 29095267
pmcid: 5682786
doi: 10.1097/MD.0000000000008396
Tamaki, S. et al. Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction. PLOS ONE 8, e68893 (2013).
pubmed: 23894370
pmcid: 3716890
doi: 10.1371/journal.pone.0068893
Ma, L. & Zhao, S. Risk factors for mortality in patients undergoing hemodialysis: A systematic review and meta-analysis. Int. J. Cardiol. 238, 151–158 (2017).
pubmed: 28341375
doi: 10.1016/j.ijcard.2017.02.095
Yang, S.-J. et al. Neutralizing IL-16 enhances the efficacy of targeting Aurora-A therapy in colorectal cancer with high lymphocyte infiltration through restoring anti-tumor immunity. Cell Death Dis. 15, 103 (2024).
pubmed: 38291041
pmcid: 10828506
doi: 10.1038/s41419-023-06381-z
Stengel, B. Chronic kidney disease and cancer: a troubling connection. J. Nephrol. 23, 253–262 (2010).
pubmed: 20349418
pmcid: 4823382
Syed-Ahmed, M. & Narayanan, M. Immune dysfunction and risk of infection in chronic kidney disease. Adv. Chronic Kidney Dis. 26, 8–15 (2019).
pubmed: 30876622
doi: 10.1053/j.ackd.2019.01.004
Lard, L. R., Roep, B. O., Verburgh, C. A., Zwinderman, A. H. & Huizinga, T. W. J. Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus 11, 181–185 (2002).
pubmed: 11999883
doi: 10.1191/0961203302lu176sr
Fava, A. et al. Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight 9, e172569 (2024).
pubmed: 38258904
pmcid: 10906224
doi: 10.1172/jci.insight.172569
Fava, A. et al. Urine proteomics and renal single cell transcriptomics implicate IL-16 in lupus nephritis. Arthr. Rheumatol. 74, 829–839 (2022).
doi: 10.1002/art.42023
Kofanova, O. et al. IL8 and IL16 levels indicate serum and plasma quality. Clin. Chem. Lab. Med. (CCLM) 56, 1054–1062 (2018).
pubmed: 29425105
doi: 10.1515/cclm-2017-1047
Betjes, M. G. H., Langerak, A. W., van der Spek, A., de Wit, E. A. & Litjens, N. H. R. Premature aging of circulating T cells in patients with end-stage renal disease. Kidney Int. 80, 208–217 (2011).
pubmed: 21525849
doi: 10.1038/ki.2011.110
Knauf, F. et al. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int. 84, 895–901 (2013).
pubmed: 23739234
pmcid: 3772982
doi: 10.1038/ki.2013.207
Luz, H. L. et al. P2X7 receptor stimulation is not required for oxalate crystal-induced kidney injury. Sci. Rep. 9, 20086 (2019).
pubmed: 31882798
pmcid: 6934555
doi: 10.1038/s41598-019-56560-2
Berbudi, A., Rahmadika, N., Tjahjadi, A. I. & Ruslami, R. Type 2 diabetes and its impact on the immune system. Curr. Diabetes Rev. 16, 442–449 (2020).
pubmed: 31657690
pmcid: 7475801
Zak, K. P., Kondratskaia, I. N., Mel’nichenko, S. V. & Popova, V. V. [Circulating interleukin-16 in blood of patients with metabolic syndrome and type 2 diabetes mellitus]. Lik Sprava 46–49 (2007).
Mohammad, D. G., Omar, H., El-Abaseri, T. B., Omar, W. & Abdelraheem, S. Association of IL-16 rs11556218 T/G polymorphism with the risk of developing type 2 diabetes mellitus. J. Diabetes Metab. Disord. 20, 649–653 (2021).
pubmed: 34222083
pmcid: 8212215
doi: 10.1007/s40200-021-00795-2
Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Eng. J. Med. 353, 238–248 (2005).
doi: 10.1056/NEJMoa043545
Wanner, C. et al. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Kidney Int. 56, S222–S226 (1999).
doi: 10.1046/j.1523-1755.1999.07158.x
Pfau, A. et al. Assessment of plasma oxalate concentration in patients With CKD. Kidney Int. Rep. 5, 2013–2020 (2020).
pubmed: 33163722
pmcid: 7609998
doi: 10.1016/j.ekir.2020.08.029